About Intersect ENT (NASDAQ:XENT)
Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Symbol: NASDAQ:XENT
- CUSIP: N/A
- Web: www.intersectent.com
Capitalization:- Market Cap: $875.67 million
- Outstanding Shares: 29,189,000
Average Prices:- 50 Day Moving Avg: $30.07
- 200 Day Moving Avg: $26.55
- 52 Week Range: $7.65 - $33.25
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -76.92
- P/E Growth: -2.44
Sales & Book Value:- Annual Revenue: $87.16 million
- Price / Sales: 10.05
- Book Value: $3.88 per share
- Price / Book: 7.73
Profitability:- EBITDA: ($19,710,000.00)
- Net Margins: -22.94%
- Return on Equity: -17.60%
- Return on Assets: -15.64%
Debt:- Current Ratio: 9.81%
- Quick Ratio: 9.17%
Misc:- Average Volume: 265,986 shs.
- Beta: 0.72
- Short Ratio: 2.34
Frequently Asked Questions for Intersect ENT (NASDAQ:XENT)
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT, Inc. (NASDAQ:XENT) posted its earnings results on Tuesday, August, 1st. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.11. The company earned $24 million during the quarter, compared to the consensus estimate of $22.62 million. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The firm's quarterly revenue was up 24.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.21) earnings per share. View Intersect ENT's Earnings History.
When will Intersect ENT make its next earnings announcement?
Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2017?
10 equities research analysts have issued 1-year price targets for Intersect ENT's shares. Their predictions range from $14.00 to $40.00. On average, they anticipate Intersect ENT's stock price to reach $27.11 in the next year. View Analyst Ratings for Intersect ENT.
What are analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (10/5/2017)
- 2. Northland Securities analysts commented, "We remain bullish on the takeout potential of this story. Key Points As a reminder, RESOLVE would be in an office" setting, hence would not be subject to the facility payment pressures currently being witnessed by PROPEL on the Medicare front. It is our understanding that the company would advocate the use of an unlisted J-code (physician administered drug) immediately after NDA approval." (3/13/2017)
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include CONMED Corporation (CNMD), MiMedx Group (MDXG), OraSure Technologies (OSUR), Asante Solutions (PUMP), Orthofix International N.V. (OFIX), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO), AtriCure (ATRC), CryoLife (CRY), Landauer (LDR), Meridian Bioscience (VIVO), Consort Medical plc (CSRT), STAAR Surgical Company (STAA), Invacare Corporation (IVC), Transenterix (TRXC), Transenterix (TRXC), Exactech (EXAC) and Antares Pharma (ATRS).
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Lisa D. Earnhardt, President, Chief Executive Officer, Director
- Jeryl L. Hilleman, Chief Financial Officer
- Richard E. Kaufman, Senior Vice President, Chief Operating Officer
- David A. Lehman, General Counsel
- Gwen Carscadden, Chief People Officer
- Kieran T. Gallahue, Lead Director
- Teresa L. Kline, Director
- William Anthony Vernon, Director
- Cynthia L. Lucchese, Independent Director
- Dana G. Mead Jr., Independent Director
Who owns Intersect ENT stock?
Intersect ENT's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Mutual of America Capital Management LLC (0.31%), Nationwide Fund Advisors (0.19%) and Strs Ohio (0.09%). Company insiders that own Intersect ENT stock include Amy Wolbeck, Frederic H Moll, James Stambaugh, Jeryl L Hilleman, Kieran Gallahue, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.
Who sold Intersect ENT stock? Who is selling Intersect ENT stock?
Intersect ENT's stock was sold by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC and Strs Ohio. Company insiders that have sold Intersect ENT stock in the last year include Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.
Who bought Intersect ENT stock? Who is buying Intersect ENT stock?
How do I buy Intersect ENT stock?
Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of Intersect ENT stock can currently be purchased for approximately $30.00.
MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Intersect ENT (NASDAQ:XENT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 8 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | $27.11 (9.63% downside) |
Consensus Price Target History for Intersect ENT (NASDAQ:XENT)
Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/13/2017 | Canaccord Genuity | Boost Price Target | Buy | $32.00 -> $37.00 | Low |  |
| 9/11/2017 | Bank of America Corporation | Boost Price Target | Buy | $33.00 -> $40.00 | High | |
| 8/22/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $35.00 | Low | |
| 8/2/2017 | Deutsche Bank AG | Set Price Target | Buy | $27.00 -> $31.00 | High | |
| 8/2/2017 | Northland Securities | Reiterated Rating | Hold | $25.00 | High | |
| 5/10/2017 | William Blair | Reiterated Rating | Outperform | | Low | |
| 5/3/2017 | Wedbush | Boost Price Target | Outperform -> Outperform | $25.00 -> $26.00 | High | |
| 12/6/2016 | Guggenheim | Initiated Coverage | Buy | $20.00 | N/A | |
| 11/4/2016 | Leerink Swann | Reiterated Rating | Outperform | $21.00 -> $14.00 | N/A | |
| 11/2/2016 | J P Morgan Chase & Co | Downgrade | Overweight -> Neutral | $25.00 -> $16.00 | N/A | |
| 8/4/2016 | BTIG Research | Reiterated Rating | Hold | $14.00 | N/A | |
| 3/24/2016 | Cantor Fitzgerald | Reiterated Rating | Buy | $29.00 | N/A | |
(Data available from 10/24/2015 forward)
Earnings History for Intersect ENT (NASDAQ:XENT)Earnings History by Quarter for Intersect ENT (NASDAQ XENT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($0.20) | | | | | N/A | |
| 8/1/2017 | Q2 2017 | ($0.19) | ($0.08) | $22.62 million | $24.00 million | View | Listen | |
| 5/2/2017 | Q1 2017 | ($0.25) | ($0.23) | $19.39 million | $20.47 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.20) | ($0.17) | $23.47 million | $24.20 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.27) | ($0.22) | $17.80 million | $18.50 million | View | N/A | |
| 8/2/2016 | Q216 | ($0.26) | ($0.21) | $18.91 million | $19.30 million | View | N/A | |
| 5/5/2016 | Q116 | ($0.29) | ($0.29) | $16.92 million | $16.69 million | View | N/A | |
| 2/23/2016 | Q415 | ($0.25) | ($0.20) | $18.36 million | $18.80 million | View | Listen | |
| 11/4/2015 | Q315 | ($0.29) | ($0.35) | $14.80 million | $14.20 million | View | N/A | |
| 8/5/2015 | Q215 | ($0.26) | ($0.23) | $14.74 million | $15.20 million | View | N/A | |
| 5/6/2015 | Q115 | ($0.33) | ($0.23) | $13.00 million | $13.37 million | View | N/A | |
| 2/26/2015 | Q414 | ($0.29) | ($0.16) | $12.20 million | $13.40 million | View | N/A | |
| 11/5/2014 | Q314 | ($0.35) | ($0.32) | $8.20 million | $9.10 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Intersect ENT (NASDAQ:XENT)2017 EPS Consensus Estimate: ($0.77)
2018 EPS Consensus Estimate: ($0.46)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | ($0.26) | ($0.22) | ($0.24) |
| Q2 2017 | 3 | ($0.19) | ($0.19) | ($0.19) |
| Q3 2017 | 3 | ($0.26) | ($0.17) | ($0.21) |
| Q4 2017 | 3 | ($0.17) | ($0.06) | ($0.13) |
| Q1 2018 | 2 | ($0.16) | ($0.08) | ($0.12) |
| Q2 2018 | 2 | ($0.12) | ($0.11) | ($0.12) |
| Q3 2018 | 2 | ($0.14) | ($0.11) | ($0.13) |
| Q4 2018 | 2 | ($0.14) | ($0.06) | ($0.10) |
(Data provided by Zacks Investment Research)
Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Intersect ENT (NASDAQ:XENT)Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 83.12%
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/16/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $28.37 | $567,400.00 | |
| 10/4/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $29.96 | $384,476.68 | |
| 9/25/2017 | Richard E Kaufman | COO | Sell | 13,639 | $28.97 | $395,121.83 | |
| 9/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $30.19 | $603,800.00 | |
| 9/5/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $31.05 | $398,464.65 | |
| 8/28/2017 | Richard E Kaufman | COO | Sell | 22,425 | $30.22 | $677,683.50 | |
| 8/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $30.79 | $615,800.00 | |
| 8/4/2017 | Jeryl L Hilleman | CFO | Sell | 12,833 | $29.00 | $372,157.00 | |
| 7/25/2017 | Richard E Kaufman | COO | Sell | 12,500 | $28.25 | $353,125.00 | |
| 7/17/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $29.03 | $580,600.00 | |
| 7/10/2017 | Jeryl L Hilleman | CFO | Sell | 12,835 | $27.18 | $348,855.30 | |
| 6/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $26.10 | $522,000.00 | |
| 5/22/2017 | Richard E Kaufman | COO | Sell | 20,000 | $22.87 | $457,400.00 | |
| 5/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $22.98 | $459,600.00 | |
| 4/20/2017 | Richard E Kaufman | COO | Sell | 1,250 | $17.25 | $21,562.50 | |
| 4/17/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $16.06 | $321,200.00 | |
| 3/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $15.02 | $300,400.00 | |
| 10/20/2016 | Richard E Kaufman | COO | Sell | 3,603 | $16.58 | $59,737.74 | |
| 10/17/2016 | Lisa D Earnhardt | Insider | Sell | 400 | $18.00 | $7,200.00 | |
| 9/7/2016 | Amy Wolbeck | VP | Sell | 28,664 | $15.83 | $453,751.12 | |
| 9/6/2016 | James Stambaugh | VP | Sell | 4,000 | $16.00 | $64,000.00 | |
| 8/3/2016 | James Stambaugh | VP | Sell | 3,977 | $17.00 | $67,609.00 | |
| 7/18/2016 | James Stambaugh | VP | Sell | 5,000 | $15.33 | $76,650.00 | |
| 6/13/2016 | James Stambaugh | VP | Sell | 500 | $14.38 | $7,190.00 | |
| 5/16/2016 | Kieran Gallahue | Director | Buy | 8,000 | $12.64 | $101,120.00 | |
| 4/27/2016 | Amy Wolbeck | VP | Sell | 2,000 | $20.01 | $40,020.00 | |
| 4/20/2016 | Richard E Kaufman | COO | Sell | 3,603 | $18.86 | $67,952.58 | |
| 4/18/2016 | Lisa D Earnhardt | CEO | Sell | 28,500 | $18.69 | $532,665.00 | |
| 3/21/2016 | Richard E Kaufman | COO | Sell | 3,603 | $16.51 | $59,485.53 | |
| 3/15/2016 | Lisa D Earnhardt | CEO | Sell | 9,000 | $18.01 | $162,090.00 | |
| 3/14/2016 | Frederic H Moll | Director | Sell | 1,299 | $18.53 | $24,070.47 | |
| 3/8/2016 | Frederic H Moll | Director | Sell | 601 | $18.56 | $11,154.56 | |
| 2/22/2016 | Richard E Kaufman | COO | Sell | 3,603 | $18.65 | $67,195.95 | |
| 1/21/2016 | Richard E. Kaufman | COO | Sell | 7,206 | $17.93 | $129,203.58 | |
| 1/15/2016 | Lisa D. Earnhardt | CEO | Sell | 12,500 | $19.26 | $240,750.00 | |
| 12/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,820 | $19.85 | $135,377.00 | |
| 11/16/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $18.00 | $122,724.00 | |
| 10/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $18.72 | $127,632.96 | |
| 9/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $25.99 | $177,199.82 | |
| 9/11/2015 | Frederic H Moll | Director | Sell | 10,000 | $25.21 | $252,100.00 | |
| 8/17/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $28.51 | $194,381.18 | |
| 7/20/2015 | James Stambaugh | VP | Sell | 12,000 | $30.52 | $366,240.00 | |
| 7/15/2015 | Lisa D Earnhardt | CEO | Sell | 19,318 | $29.62 | $572,199.16 | |
| 6/15/2015 | Lisa D Earnhardt | CEO | Sell | 19,318 | $29.30 | $566,017.40 | |
| 5/8/2015 | James Stambaugh | VP | Sell | 2,785 | $23.87 | $66,477.95 | |
| 4/13/2015 | Amy Wolbeck | VP | Sell | 16,000 | $26.25 | $420,000.00 | |
| 4/1/2015 | James Stambaugh | VP | Sell | 8,343 | $25.50 | $212,746.50 | |
| 3/16/2015 | Lisa D Earnhardt | Insider | Sell | 19,318 | $23.56 | $455,132.08 | |
| 3/11/2015 | Amy Wolbeck | VP | Sell | 8,000 | $23.06 | $184,480.00 | |
| 3/9/2015 | James Stambaugh | VP | Sell | 8,343 | $23.02 | $192,055.86 | |
| 2/17/2015 | Lisa D Earnhardt | Insider | Sell | 19,318 | $22.69 | $438,325.42 | |
| 2/12/2015 | Amy Wolbeck | VP | Sell | 8,000 | $22.12 | $176,960.00 | |
| 2/2/2015 | James Stambaugh | VP | Sell | 8,343 | $20.98 | $175,036.14 | |
| 1/26/2015 | Robert H Binney Jr | VP | Sell | 6,300 | $21.18 | $133,434.00 | |
| 9/11/2014 | Cynthia L Lucchese | Director | Buy | 5,000 | $17.11 | $85,550.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Intersect ENT (NASDAQ:XENT)
Latest Headlines for Intersect ENT (NASDAQ:XENT)
| Source: |
|
Loading headlines, please wait.
Intersect ENT (XENT) Chart for Tuesday, October, 24, 2017
